Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, July 17, 2023
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
[ Mon, Jul 17th 2023
] - WOPRAI
Vikram Purohit Reiterated (ASND) at Hold and Held Target at $109 on, Jul 17th, 2023
Vikram Purohit of Morgan Stanley, Reiterated "Ascendis Pharma A/S" (ASND) at Hold and Held Target at $109 on, Jul 17th, 2023.
Vikram has made no other calls on ASND in the last 4 months.
There are 6 other peers that have a rating on ASND. Out of the 6 peers that are also analyzing ASND, 2 agree with Vikram's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Tiago Fauth of "Credit Suisse" Initiated at Hold and Held Target at $89 on, Wednesday, June 14th, 2023
- Leland Gershell of "Oppenheimer" Downgraded from Buy to Hold on, Wednesday, April 5th, 2023
These are the ratings of the 4 analyists that currently disagree with Vikram
- Andreas Argyrides of "Wedbush" Reiterated at Buy and Held Target at $187 on, Wednesday, June 7th, 2023
- Li Watsek of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $152 on, Thursday, June 1st, 2023
- David Lebowitz of "Citigroup" Maintained at Strong Buy with Decreased Target to $146 on, Wednesday, April 5th, 2023
- Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Decreased Target to $92 on, Tuesday, April 4th, 2023
